UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2017
SPRING BANK PHARMACEUTICALS, INC.
(Exact Name of Company as Specified in Charter)
Delaware | | 001-37718 | 52-2386345 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | (IRS Employer Identification No.) |
86 South Street
Hopkinton, MA 01748
(Address of Principal Executive Offices) (Zip Code)
Company’s telephone number, including area code: (508) 473-5993
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07 Submission of Matters to a Vote of Security Holders
Spring Bank Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 15, 2017. The following is a summary of the matters voted on at that meeting.
| a) | The stockholders of the Company elected David Arkowitz and Kurt Eichler as class II directors, each to serve for a three-year term expiring at the 2020 annual meeting of stockholders. The results of the stockholders’ vote with respect to the election of the class II directors were as follows: |
| | | | | | | | | | | | |
Name | | Votes For | | | Votes Withheld | | | Broker Non-
Votes | |
David Arkowitz | | | 3,015,121 | | | | 40,467 | | | | 2,873,032 | |
Kurt Eichler | | | 2,795,144 | | | | 260,444 | | | | 2,873,032 | |
| b) | The stockholders of the Company ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2017. The results of the stockholders’ vote with respect to such ratification were as follows: |
| | | | | | |
For | | Against | | Abstain | | Broker Non-Votes |
5,885,081 | | 29,833 | | 13,706 | | 0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SPRING BANK PHARMACEUTICALS, INC.
| | | |
| | |
| | | |
Date: June 15, 2017 | | By: | /s/ Martin Driscoll |
| | | Martin Driscoll |
| | | President and Chief Executive Officer |
